PRE-CLINICAL STUDIES FOR ADVANCING CIRMTUZUMAB-BASED ANTI-ROR1 THERAPIES IN METASTATIC PROSTATE CANCER

被引：0
|
作者：
Muldong, Michelle
Lee, Sanghee
Mendoza, Theresa
Burner, Danielle
Wu, Christina
Murtadha, Jamillah
Koutouan, Evodie
Pineda, Naomi
Pineda, Gabriel
Lennon, Kathleen
Hao Pham
Willert, Karl
Cacalano, Nicholas
Jamieson, Catriona
Gaasterland, Terry
Kane, Christopher
Kulidjian, Anna
Jamieson, Christina
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD07-04
引用
收藏
页码：E99 / E99
页数：1
相关论文
共 50 条
  • [41] Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer
    Awasthi, Niranjan
    Mikels-Vigdal, Amanda J.
    Stefanutti, Erin
    Schwarz, Margaret A.
    Monahan, Sheena
    Smith, Victoria
    Schwarz, Roderich E.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (06) : 3878 - 3887
  • [42] Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
    N Johnson
    J Bentley
    L-Z Wang
    D R Newell
    C N Robson
    G I Shapiro
    N J Curtin
    British Journal of Cancer, 2010, 102 : 342 - 350
  • [43] Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
    Johnson, N.
    Bentley, J.
    Wang, L-Z
    Newell, D. R.
    Robson, C. N.
    Shapiro, G. I.
    Curtin, N. J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (02) : 342 - 350
  • [44] Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
    Johnson, N.
    Bentley, J.
    Wang, L-Z
    Newell, D. R.
    Robson, C. N.
    Shapiro, G. I.
    Curtin, N. J.
    BRITISH JOURNAL OF CANCER, 2024, : 955 - 955
  • [45] Pre-Clinical Proof of Concept and Characterization of AEZS-120: A Therapeutic Oral Prostate Cancer Vaccine Candidate Based on Live Recombinant Attenuated Salmonella
    Fensterle, J.
    Bergmann, B.
    Teifel, M.
    Engel, J.
    Rudel, T.
    Goebel, W.
    Rapp, U.
    UROLOGY, 2012, 80 (03) : S297 - S298
  • [46] High affinity and potent anti-tumor efficacy of Nivo813, an anti-PD-1/ALK-1 bispecific antibody, in pre-clinical studies for solid tumors
    Zhou, Qingqing
    Tang, Rong
    Zhuang, Lanfang
    Huang, Jianyu
    Qian, Jiang
    Ren, Zhihua
    Tong, Youzhi
    CANCER RESEARCH, 2024, 84 (06)
  • [47] The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
    A P Toner
    F McLaughlin
    F J Giles
    F J Sullivan
    E O'Connell
    L A Carleton
    L Breen
    G Dunne
    A M Gorman
    J D Lewis
    S A Glynn
    British Journal of Cancer, 2013, 109 : 2131 - 2141
  • [48] The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
    Toner, A. P.
    McLaughlin, F.
    Giles, F. J.
    Sullivan, F. J.
    O'Connell, E.
    Carleton, L. A.
    Breen, L.
    Dunne, G.
    Gorman, A. M.
    Lewis, J. D.
    Glynn, S. A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (08) : 2131 - 2141
  • [49] Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium
    Newton, Meredith
    Burkett, Wesley
    Zhao, Ziyi
    Secord, Angeles Alvarez
    Zhou, Chunxiao
    Bae-Jump, Victoria
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S31 - S31
  • [50] Eradication of tumors in pre-clinical models of multiple myeloma by Anti-CS1 monoclonal antibody HuLuc63: Mechanism of action studies.
    Rice, Audie
    Dillon, Myles
    van Abbema, Anne
    Jesaitis, Lynne
    Wong, Melanie
    Lawson, Stacey
    Liu, Gao
    Zhang, Yin
    Powers, David
    Rhodes, Susan
    Caras, Ingrid
    Law, Debbie
    Afar, Daniel
    BLOOD, 2006, 108 (11) : 999A - 999A
12345